Almac’s Predictive Assay for Immune Response Agents
This gene expression based assay identifies a molecular subgroup of cancers that exhibit activation of immune checkpoint proteins such as PD-L1 and ID01, which results in immune system evasion and cancer cell survival.
Almac is developing this assay as a means of prospectively identifying patients likely to respond to PD-L1 targeted therapies.
This assay has the potential to be used as a companion diagnostic for immune checkpoint inhibitor based therapy across a range of disease areas.
Validation of the underlying biology which connects immune checkpoint activation to DNA damage has been published in the Journal of the National Cancer Institute.